|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.18 CNY | +4.44% |
|
+6.84% | -2.50% |
| 04-24 | Dashenlin Pharma's Q1 Profit Rises 11% | MT |
| 04-24 | Dashenlin Pharma's 2025 Profit Jumps 35%, Revenue Rises 4% | MT |
Company Valuation: DaShenLin Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 33,307 | 37,585 | 28,359 | 17,151 | 20,066 | 19,565 | - | - |
| Change | - | 12.85% | -24.55% | -39.52% | 17% | -2.5% | - | - |
| Enterprise Value (EV) 1 | 32,838 | 36,233 | 27,369 | 15,778 | 16,831 | 16,046 | 15,556 | 15,147 |
| Change | - | 10.34% | -24.46% | -42.35% | 6.67% | -4.66% | -3.06% | -2.62% |
| P/E Ratio | 42.1x | 36.3x | 24.2x | 18.6x | 16.3x | 13.2x | 11.5x | 10x |
| PBR | 6.3x | 6.24x | 4.16x | 2.49x | 2.72x | 2.47x | 2.25x | 2.09x |
| PEG | - | 1.2x | 1.8x | -0.9x | 0.5x | 0.6x | 0.8x | 0.7x |
| Capitalization / Revenue | 1.99x | 1.77x | 1.16x | 0.65x | 0.73x | 0.65x | 0.59x | 0.53x |
| EV / Revenue | 1.96x | 1.71x | 1.12x | 0.6x | 0.61x | 0.54x | 0.47x | 0.41x |
| EV / EBITDA | 13.6x | 19.2x | 12.9x | 4.65x | 4.39x | 4.27x | 3.66x | 3.16x |
| EV / EBIT | 31.6x | 25.5x | 16.8x | 10.5x | 8.26x | 7.04x | 5.93x | 5.06x |
| EV / FCF | 117x | 13.1x | 19.7x | 9.51x | 3.44x | 15.9x | 7.61x | 6.19x |
| FCF Yield | 0.86% | 7.61% | 5.09% | 10.5% | 29.1% | 6.29% | 13.1% | 16.2% |
| Dividend per Share 2 | 0.3472 | 0.5 | 0.31 | 0.31 | 0.49 | 0.8819 | 0.9337 | 1.181 |
| Rate of return | 1.19% | 1.52% | 1.24% | 2.06% | 2.78% | 5.13% | 5.43% | 6.87% |
| EPS 2 | 0.6944 | 0.9083 | 1.03 | 0.81 | 1.08 | 1.304 | 1.494 | 1.717 |
| Distribution rate | 50% | 55% | 30.1% | 38.3% | 45.4% | 67.7% | 62.5% | 68.8% |
| Net sales 1 | 16,759 | 21,248 | 24,531 | 26,497 | 27,502 | 29,969 | 33,013 | 36,680 |
| EBITDA 1 | 2,408 | 1,883 | 2,119 | 3,395 | 3,833 | 3,761 | 4,251 | 4,791 |
| EBIT 1 | 1,041 | 1,421 | 1,632 | 1,501 | 2,038 | 2,278 | 2,621 | 2,993 |
| Net income 1 | 791.2 | 1,036 | 1,166 | 914.8 | 1,235 | 1,485 | 1,702 | 1,954 |
| Net Debt 1 | -469.2 | -1,352 | -989.8 | -1,373 | -3,236 | -3,519 | -4,010 | -4,418 |
| Reference price 2 | 29.24 | 33.00 | 24.90 | 15.06 | 17.62 | 17.18 | 17.18 | 17.18 |
| Nbr of stocks (in thousands) | 1,138,968 | 1,138,947 | 1,138,902 | 1,138,848 | 1,138,848 | 1,138,848 | - | - |
| Announcement Date | 27/04/22 | 27/04/23 | 28/04/24 | 25/04/25 | 23/04/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 12.62x | 0.51x | 4.05x | 5.36% | 2.76B | |
| 18.05x | 0.75x | 11.89x | -.--% | 15.53B | |
| 21.1x | 1.04x | 16.12x | -.--% | 7.03B | |
| 16.55x | 0.72x | 7.5x | 2.05% | 5.78B | |
| 13.14x | 0.84x | 6.04x | 3.27% | 3.73B | |
| 16.16x | 0.98x | 7.34x | 3.99% | 3.33B | |
| 14.59x | 1.23x | 7.51x | 5.67% | 3.26B | |
| 42.03x | - | - | - | 2.73B | |
| 24.11x | 0.68x | 8.84x | 1.7% | 1.75B | |
| Average | 19.81x | 0.85x | 8.66x | 2.76% | 5.1B | |
| Weighted average by Cap. | 18.87x | 0.84x | 10.18x | 1.71% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 603233 Stock
- Valuation DaShenLin Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
